1,091 results

#213815-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_ChR2_mCherry (#213815). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#213855-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#214852-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14033: pAAV-AiE0779m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4033) (#214852). In addition to the viral particles, you will also receive purified AiP14033: pAAV-AiE0779m_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4033) plasmid DNA. minBG-driven expression of CoChR-EGFP in striatal direct pathway medium spiny neurons (D1 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#105540-AAV2

Ready-to-use AAV2 particles produced from pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 (#105540). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. Expression of EGFP-Cre from hSyn promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 21, 2024

Academic Institutions and Nonprofits only

#198516-AAV5

Ready-to-use AAV5 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#105547-PHPeB

Ready-to-use AAV PHP.eB particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Feb. 16, 2024

Academic Institutions and Nonprofits only

#162382-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE (#162382). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of the ultrafast calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Sept. 27, 2023

Academic Institutions and Nonprofits only

#179255-AAV1

Ready-to-use AAV1 particles produced from AAV-CAG-jGCaMP8m-WPRE (#179255). In addition to the viral particles, you will also receive purified AAV-CAG-jGCaMP8m-WPRE plasmid DNA. CAG-driven expression of calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Sept. 27, 2023

Academic Institutions and Nonprofits only

#105547-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Sept. 13, 2021

Academic Institutions and Nonprofits only

#162382-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE (#162382). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8f-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of the ultrafast calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Sept. 13, 2021

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#83897-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only

#50363-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-DreO-bGHpA (#50363). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-DreO-bGHpA plasmid DNA. hSyn-driven Dre recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

Aug. 18, 2020

Academic Institutions and Nonprofits only

#83896-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

June 1, 2020

Academic Institutions and Nonprofits only

#100832-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.CaMPARI.WPRE.SV40 (#100832). In addition to the viral particles, you will also receive purified pAAV.hSyn.CaMPARI.WPRE.SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator. These AAV preparations are suitable purity for injection into animals.

Loren Looger, Eric Schreiter

Fosque et al Science. 2015 Feb 13;347(6223):755-60. d

April 6, 2018

Academic Institutions and Nonprofits only

#98932-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 (#98932). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.iGluSnFr.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

Feb. 28, 2018

Academic Institutions and Nonprofits only

#179529-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-4mtGCaMP6f-DIO (#179529). In addition to the viral particles, you will also receive purified pAAV-EF1a-4mtGCaMP6f-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only

#20299-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA (#20299). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-mCherry-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#34910-AAV5

Ready-to-use AAV5 particles produced from paavCAG-pre-mGRASP-mCerulean (#34910). In addition to the viral particles, you will also receive purified paavCAG-pre-mGRASP-mCerulean plasmid DNA. CAG-driven expression of presynaptic mGRASP-mCerulean for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#196219-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR (#196219). In addition to the viral particles, you will also receive purified pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR plasmid DNA. CAG-driven, Cre-dependent third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

Aug. 6, 2025

Academic Institutions and Nonprofits only